Depei Wu

Featured in: Favicon

nature.com Favicon

science.org Favicon

dovepress.com Favicon

futuremedicine.com Favicon

medsci.org Favicon

onlinelibrary.wiley.com

Articles

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT - Bone Marrow Transplantation

Aug 1, 2024 | nature.com | Myriam Labopin |Depei Wu |Mahmoud Aljurf |Edouard Forcade |Jakob Passweg |Thomas Pabst | +7 more

AbstractCore-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction followed by high-dose cytarabine (HiDAC) consolidation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is reserved for relapse or for patients having not achieved MRD-negativity at high risk for relapse.
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study | Bone Marrow Trans

Apr 12, 2024 | nature.com | Depei Wu

T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy with 5-year overall survival (OS) of less than 60% in adults and 85% in children due to improved intensive therapies [1,2,3]. Over the past few decades, allogeneic hematopoietic stem-cell transplantation (allo-HSCT) has been proved to improve the prognosis and even be a potential cure for T-ALL [1].

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →